Company news

Immuneering Corporation news in 2025

Immuneering Corporation's news releases, calls and decks from 2025, newest first.

View company

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

December 23, 2025

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

December 17, 2025

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

December 16, 2025

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

November 12, 2025

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

November 4, 2025

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

September 26, 2025

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

September 25, 2025

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

September 24, 2025

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

September 24, 2025

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

September 16, 2025

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

September 10, 2025

Immuneering Announces Closing of $25 Million Private Placement

August 26, 2025

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

August 25, 2025

Immuneering Announces $25 Million Private Placement

August 21, 2025

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13, 2025

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

July 9, 2025

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

June 17, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

June 16, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025

Immuneering Corporation Announces Grant of Inducement Award

March 21, 2025

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 20, 2025

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

March 20, 2025

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

February 5, 2025

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

January 12, 2025

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

January 6, 2025

Calls in 2025

Decks in 2025